Early Birds Get FDA Worrying: How To Handle Quick Biosimilar Applications?
You may also be interested in...
Biosimilars: FDA Trying Group-Think Negotiating Strategy For User Fee
FDA seems content to negotiate a user fee for biosimilars in a manner that typifies the composition of the products: similar, but not the same, as the other user fee programs.
As Japan’s Syphilis Cases Surge, So Do Calls For More Therapeutics
As Japan faces skyrocketing syphilis cases, hopes have been high among domestic physicians for a single-dose therapeutic in the form of benzylpenicillin injection. But the country has approved the drug only recently and in answer to a push from doctors on the front line.